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Abstract
Background: At a U.S prevalence of 1 in 3000, Neurofibromatosis type-1 (NF-1) is a relatively
common disorder. Amongst a variety of others, occurrence of 2 or more neurofibromas in the
same patient represents one of the major diagnostic criteria for this disorder. Rarely, ocular,
cutaneous or anorectal malignant melanomas may be identified in patients with NF-1, This rare
association has caused controversy as to whether patients with NF-1 have an inherently higher risk
for melanomas or whether the associations can be explained by chance alone.
Case presentation: The purpose of this report is to highlight the unusual confluence of rare
clinicopathologic features in a patient without NF-1. The patient was diagnosed with an 8.5 cm pre-
sacral neurofibroma and was shortly thereafter diagnosed with a cutaneous malignant melanoma
showing spitzoid features. Pre-sacral neurofibromas are rare in patients without NF-1; likewise,
malignant spitzoid melanoma, a controversial histopathological entity, is distinctly uncommon.
Conclusions: The synchronous diagnoses of these neural crest derived tumor entities in a patient
without neurofibromatosis lends credence to the view that when these two lesions occur in
patients with NF-1, the association is  coincidental.
Background
Neurofibromatosis type-1 (NF-1) is a common autosomal
dominant disorder characterized by multiple neurofibro-
mas, café-au-lait spots, freckling of the inguinal or axillary
regions, gliomas, iris hamartomas, and malignant periph-
eral nerve sheath tumors [1,2]. Neurofibromas are typi-
cally well-delineated and are composed of an admixture
of various cell types, such as Schwann cells, fibroblasts
and perineural-like cells and cells showing intermediate
features [1,2]. Although as outlined above, multiple neu-
rofibromas are characteristic of patients with NF-1, how-
ever, most cases of neurofibroma which are diagnosed in
general are sporadic in nature. The vast majority of neu-
rofibromas are cutaneous and less commonly are
intraneural, within the soft tissues or viscera. Presacral
neurofibromas or neurofibromas with presacral involve-
ment are uncommon in patients without NF-1, and have
been the subject of sporadic case reports over the past
half-century [3-16]. Likewise, spitzoid melanoma or
melanomas showing spitzoid-like features form only a
small percentage of all malignant melanomas. This diag-
nosis is based on the rare finding that some melanomas
displays cytologic features that are similar to those identi-
fied in the benign Spitz nevus [17]. The controversy asso-
ciated with this lesion stems from the fact that some
dermatopathologists do not believe in its existence and
prefer to designate melanocytic proliferations meeting tra-
ditional criteria for malignancy as malignant melanomas,
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irrespective of the Spitzoid features [18]. To our knowl-
edge, a synchronous presacral neurofibroma and cutane-
ous spitzoid melanoma have never been reported in a
patient without neurofibromatosis. More importantly, the
absence of NF-1 in our patient may have implications for
the potential association between malignant melanoma
and NF-1.
Case presentation
In September 2000, a 35-year-old female without any his-
tory or clinical stigmata of NF-1 presented to her primary
physician with complaints of a dull, localized left upper
leg pain of several months' duration. An abdominal mass
was palpated during a physical examination. Magnetic
resonance imaging (MRI) as well as a computed tomo-
graphic (CT) scan of the abdomen and pelvis showed a
large well-defined, near spherical mass in the left false pel-
vis which enhanced heterogeneously at a mean Houns-
field value of 44 units (Figure 1). The mass displaced the
external iliac vein medially and psoas muscle laterally. It
also abutted the upper surface of the left ovary without
truly invading any of these or other surrounding struc-
tures. However, the mass was believed to be in the course
of the left genitofemoral nerve and lumbar plexus. The
decision was made to resect the mass. Intraoperatively, the
tumor's capsule was found to be densely adhered medi-
ally to the external iliac vessels, with at least 10 external
venous branches directly supplying the tumor. The tumor
was carefully marsupialized out of the retroperitoneal area
and the decision was made to leave the residual capsule,
since an attempt at its removal would have entailed a
highly morbid procedure that was not felt to be justified
based on the histopathologic appearance of the tumor on
frozen sections. Intraoperatively, a pigmented macular
lesion with faintly irregular edges was noted in the left
upper thigh, which was biopsied. Pathologic examination
showed a malignant melanoma with spitzoid features.
The precise circumstances regarding the duration of the
lesion and whether there had been any increase in its size
was unclear. She subsequently underwent a wide local
excision (4 × 12 cm skin ellipse was removed) and senti-
nel lymph node biopsy, both of which showed no resid-
ual melanoma. The patient's postoperative course over the
subsequent 2 years was remarkable for a relatively slow
but progressive improvements in the neurologic symp-
toms related to her surgery. However, she showed no evi-
dence of either tumor recurrence at last follow-up, 26
months postoperatively.
Pathologic findings
The resected mass was spherical, weighed 270 grams and
measured 8.5 × 7 cm × 7 cm (figure 2). The specimen was
sectioned to reveal a myxoid tan-yellow cut surface (figure
3). Microscopically, the specimen was uniformly hypocel-
lular, and showed a haphazard admixture of wavy
Schwann cells and collagen fibers dispersed in a mucopol-
ysaccharide matrix (figure 4). No increased cellularity,
nuclear pleomorphism, increased mitotic activity or
tumor coagulative cell necrosis was identified. On immu-
nohistochemistry the tumor was positive for S100, Neuro-
filament, vimentin, and negative for epithelial membrane
antigen, in combination with the morphological features
a diagnosis of neurofibroma was made. Pathologic exam-
ination of the skin lesion showed a malignant melanoma
(6 mm in diameter) with spitzoid features: epithelioid
and spindle atypical melanocytes growing in a solid,
asymmetric, non-maturing pattern with deep mitotic fig-
ures (up to 3 mitotic figures/mm2). The individual cells
displayed nuclear pleomorphism with prominent nucle-
oli and the epithelioid forms showed abundant cytoplasm
(Figures 5, 6, 7, 8). Immunohistochemically, both the
spindle and epithelioid cells showed strong and diffuse
immunoreactivity for S100 and HMB-45. The prolifera-
tive index of the tumor was 30–40% as assessed with the
immunohistochemical marker ki-67. This lesion was at a
Clark's level IV and at a depth of 2.1 mm. Growth phase
was vertical and ulceration was absent. A few tumor-infil-
trating lymphocytes were present and there was no defin-
itive evidence of regression.
Discussion
The potential association between NF-1 and malignant
melanoma has been the source of controversy in the med-
ical literature. The common neural crest origin of these
conditions has provided an attractive framework for this
discussion. However, it is unclear whether patients with
NF-1 have an inherently higher propensity to develop
malignant melanomas than the general population. In a
Computed tomographic scan of the pelvis showing a large,  well-circumscribed presacral mass Figure 1
Computed tomographic scan of the pelvis showing a large, 
well-circumscribed presacral massWorld Journal of Surgical Oncology 2004, 2:31 http://www.wjso.com/content/2/1/31
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follow-up study of 70 NF-1 patients reported to the Swed-
ish Cancer registry, 24% of the 70 patients developed 19
malignancies, only 1 of which was a melanoma [19].
However, the precise prevalence of melanomas in NF-1
patients is largely unknown. Most melanomas that arise
in the setting of NF-1 are ocular. In a recent literature
review, Honavar et al [20] identified only 19 reported
cases overall. Cutaneous and anorectal melanomas have
also been rarely reported in patients with NF-1 [21-27].
The rarity of this association given the frequency of NF-1
(1 in 3000) suggests that the probability of NF-1 patients
developing malignant melanoma is no more than the
general population. However, this needs to be tested in a
Macroscopic appearance of the external surface of the pre- sacral mass Figure 2
Macroscopic appearance of the external surface of the pre-
sacral mass
The cut surface of the presacral mass showing glistening  myxoid, tan-yellow appearance Figure 3
The cut surface of the presacral mass showing glistening 
myxoid, tan-yellow appearance
Microscopic appearance of the presacral mass showing a hap- hazard admixture of wavy Schwann cells and collagen fibers  dispersed in a mucopolysaccharide matrix (Hematoxylin and  Eosin, 20×) Figure 4
Microscopic appearance of the presacral mass showing a hap-
hazard admixture of wavy Schwann cells and collagen fibers 
dispersed in a mucopolysaccharide matrix (Hematoxylin and 
Eosin, 20×)
Photomicrographic panoramic view of the patient's cutane- ous biopsy showing an asymmetric lesion with a basal conflu- ent growth (Hematoxylin and Eosin 2×) Figure 5
Photomicrographic panoramic view of the patient's cutane-
ous biopsy showing an asymmetric lesion with a basal conflu-
ent growth (Hematoxylin and Eosin 2×)World Journal of Surgical Oncology 2004, 2:31 http://www.wjso.com/content/2/1/31
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rigorous population-based study. Ishii et al [21] recently
reported a loss of heterozygosity (LOH) at the NF-1 gene
in an anal melanoma occurring in an NF-1 patient. This
suggests that the well-known Knudson's two-hit hypothe-
sis may be operational, and that somatic loss of the sec-
ond allele of the putative tumor suppressor function of
the NF-1 gene causes development of this particular
somatic malignancy. Again, more cases need to be studied
to exclude the possibility that LOH for NF-1 occuring as a
late event in the tumorigenesis of sporadic melanomas.
Our case provides another framework for the discussion
of the potential association between NF-1 and malignant
melanoma. Our patient has no evidence of either of the
neurofibromatosis syndromes. The rarity of the clinico-
pathologic features of both lesions identified in this
patient (the unusual presacral location of the neurofi-
broma and the spitzoid melanoma) suggests that their
association in this patient is coincidental, even though
both are neural crest derived neoplasms. This presump-
tion contradicts the notion that in patients with NF-1,
malignant melanomas that rarely develop are part of their
neurocristopathy. For residents of the United States, the
lifetime probability of developing cutaneous melanoma is
1 in 55–82 (approximately 1.5%) [28]. As previously
noted, NF-1 is a relatively common condition with a prev-
alence of 1 in 3000. Since no more than 100 cases of
melanoma (all sites combined) developing in NF-1
patients have been reported, the incidence is significantly
lesser than the 1.5% that can be attributed to chance
alone.
Although the patient described in this report did not have
characteristic clinical features of NF-1, an important pos-
sibility that requires consideration is that she has segmen-
tal NF-1. Segmental NF-1 is thought to result from a post-
zygotic mutation in the NF-1 gene resulting in a somatic
mosaicism [29,30]. In these patients, characteristic NF-1-
Photomicrograph of the junctional component of the tumor  showing Spitzoid features of the lesional cells Figure 6
Photomicrograph of the junctional component of the tumor 
showing Spitzoid features of the lesional cells. Note that the 
junctional nests do not display a uniform vertical orientation 
towards the epidermis, as is expected in most Spitz nevi. 
(Hematoxylin and Eosin 40×)
Interemediate-power view of the cutaneous lesional cells,  showing the admixture of spindle and epithelioid cells  (Hematoxylin and Eosin 20×) Figure 7
Interemediate-power view of the cutaneous lesional cells, 
showing the admixture of spindle and epithelioid cells 
(Hematoxylin and Eosin 20×)
Photomicrograph showing the cytologic features of the  lesion Figure 8
Photomicrograph showing the cytologic features of the 
lesion. Note the nuclear pleomorphism and prominent nucle-
oli. This focus was near the deep edge of the lesion, reflecting 
a lack of histological maturation (Hematoxylin and Eosin 20×)World Journal of Surgical Oncology 2004, 2:31 http://www.wjso.com/content/2/1/31
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associated diseases are limited to a localized part of the
body [29,30]. In our patient, a presacral neurofibroma
was associated with an upper thigh cutaneous melanoma,
putting both lesions in the general same region, albeit
without true co-localization. Additionally, melanoma is
not a diagnostic criteria for NF-1, as associated lesions are
required to be for the definition of segmental NF-1. The
location of the current patient's neurofibroma is also
somewhat unusual for segmental NF-1. In two combined
series that investigated 163 patients with segmental NF-1,
there was not a single case of a retroperitoneal neurofi-
broma [29,30]. In one of these series [29], neurofibromas
alone were the most common manifestation of segmental
NF-1. However, in all such cases, the neurofibromas were
either dermal, on major peripheral nerve trunks or both.
Although these findings argue against segmental NF-1 in
the current patient, the possibility certainly remains. Thus,
the findings in this case should be viewed within the con-
text of that possibility.
In conclusion, we report here the previously unreported
synchronous diagnosis of a presacral neurofibroma and a
spitzoid malignant melanoma in a patient without NF-1.
Furthermore, the finding of a sporadic neurofibroma and
malignant melanoma occurring in a patient without NF-1
lends credence to the view that when these lesions occur
in patients with NF-1, the association may be
coincidental.
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